TOCILIZUMAB, MOXIFLOXACIN, CLARITHROMYCIN, ERYTHROMYCIN LACTOBIONATE, PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , CEFTRIAXONE, BARICITINIB, HYDROCORTISONE, DEXAMETHASONE, ROXITHROMYCIN, LEVOFLOXACIN, BALOXAVIR MARBOXIL, AZITHROMYCIN, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , AZITHROMYCIN, IMATINIB, OSELTAMIVIR, CLARITHROMYCIN, DEXAMETHASONE, ERYTHROMYCIN
NCT02735707
Phase 3 small_molecule active
Quick answer
TOCILIZUMAB, MOXIFLOXACIN, CLARITHROMYCIN, ERYTHROMYCIN LACTOBIONATE, PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , CEFTRIAXONE, BARICITINIB, HYDROCORTISONE, DEXAMETHASONE, ROXITHROMYCIN, LEVOFLOXACIN, BALOXAVIR MARBOXIL, AZITHROMYCIN, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , AZITHROMYCIN, IMATINIB, OSELTAMIVIR, CLARITHROMYCIN, DEXAMETHASONE, ERYTHROMYCIN for Respiratory tract infection is a Phase 3 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- Respiratory tract infection
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active